Navigation Links
Two New Strategic Reports Expand Coverage Of BioTrend's Biosimilars Advisory Service
Date:4/1/2013

EXTON, Pa., April 1, 2013 /PRNewswire/ -- BioTrends Research Group, one of the world's leading research and advisory firms for specialized biopharmaceutical issues, has released two strategic components to its 2013 Biosimilars Advisory Service, which provides vital business planning insights and analysis in the evolving biosimilars space. The reports entitled Corporate Strategies and Global Pipelines, Pathways and Key Stakeholder Perspectives of Biosimilars analyze surveyed opinions of specialist physicians and payers in the United States and Europe and secondary market research to uncover critical trends in strategic development for commercially lucrative market segments.

"The Biosimilars Advisory Service has always been a highly valuable tool for understanding trends in a complex and dynamic market," said Andrew Merron , Ph.D., Senior Director, Biosimilars Research at Decision Resources Group. "These new reports aim to enhance the overall service by evaluating current market opinion to help understand globally focused business strategies, regulatory guidance in multiple markets and pipeline information."

BioTrends Research Group's Biosimilars Advisory Service also includes quarterly webinars detailing major industry developments, analyst insight addressing key market changes, therapeutic area-specific primary research and interactive annualized 10-year forecasts.

About BioTrends Research Group
BioTrends Research Group provides syndicated and custom primary market research to pharmaceutical manufacturers competing in clinically evolving, specialty pharmaceutical markets. For information on BioTrends publications and research capabilities, please visit www.Bio-Trends.com. BioTrends is a Decision Resources Group company.

About Decision Resources Group
Decision Resources Group is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources Group at www.DecisionResourcesGroup.com.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

 For more information, contact:BioTrends Research Group Decision Resources GroupAllison Thrower

Liz Marshall781-993-2604

781-993-2563athrower@dresourcesgroup.com

emarshall@dresourcesgroup.com


'/>"/>
SOURCE BioTrends Research Group
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Neuro Intervention Market: New Strategic Landscape & Market Forecast
2. MDHI Receives Strategic Investment to Continue Strong Growth - Moves into Positive Operating Cash Flow for March 2013 Quarter
3. Saladax Biomedical Receives $22.4 Million Strategic Equity Investment From Shanghai Fosun Pharmaceutical
4. DDS Lab Announces Strategic Alliance with United Concordia
5. Presage Biosciences Announces Strategic Research Alliance with Celgene Corporation
6. Evofem Announces Strategic Alliance with WomanCare Global
7. WebMD and Qualcomm Life Launch Strategic mHealth Collaboration
8. Imalux Corporation Engages Advisor to Explore Strategic Options
9. BioDrain Medical Retains KCSA Strategic Communications as Corporate Communications Counsel
10. Mylan Enhances Partnership with Biocon through Strategic Collaboration for Insulin Products
11. Covaris and HORIBA Instruments Form Strategic Relationship
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... 2017   Divoti USA will engrave and ... standard of the latest FDA requirements, which stipulates new criteria regarding ... in need of Medical ID jewelry such as Medical ID Bracelets, ... engraved in terms of the new FDA requirements . ... Divoti offers this dark mark fiber ...
(Date:10/11/2017)... , Oct. 11, 2017  Caris Life Sciences ... on fulfilling the promise of precision medicine, today announced ... joined Caris, Precision Oncology Alliance™ (POA) as its 17 ... centers, the St. Jude Crosson Cancer Institute will help ... the use of tumor profiling, making cancer treatment more ...
(Date:10/10/2017)... Oct. 10, 2017  NDS received FDA 510(k) clearance in May ... battery-powered display stand specifically designed for endoscopy environments. An innovative secondary ... a clinical solution to support the improvement of patient outcomes, procedural ... ... ...
Breaking Medicine Technology:
(Date:10/13/2017)... LUIS OBISPO, Calif. (PRWEB) , ... October 13, 2017 , ... ... Alzheimer’s or dementia. However, many long-term care insurance companies have a waiver for care ... is the 90-day elimination period, when the family pays for care, is often waived, ...
(Date:10/13/2017)... ... 13, 2017 , ... Yisrayl Hawkins, Pastor and Overseer at The House of ... popular and least understood books in the Holy Scriptures, Revelation. The Book of Revelation ... scholars for centuries. Many have tossed it off as mere rubbish, but Yisrayl Hawkins ...
(Date:10/13/2017)... ... ... On The Brink”: the Christian history of the United States and the loss of ... William Nowers. Captain Nowers and his wife, Millie, have six children, ten grandchildren, ... Navy. Following his career as a naval aviator and carrier pilot, he spent ...
(Date:10/12/2017)... ... October 12, 2017 , ... The company has developed ... consumer and regulatory authorities worldwide. From Children’s to Adults 50+, every formula has ... highest standard. , These products are also: Gluten Free, Non-GMO, Vegan, Soy ...
(Date:10/12/2017)... ... October 12, 2017 , ... Information about the technology: , ... to enable prevention of a major side effect of chemotherapy in children. Cisplatin ... patients. For cisplatin, hearing loss is FDA listed on-label as a dose limiting ...
Breaking Medicine News(10 mins):